400 Stock Overview
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Relmada Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.52 |
| 52 Week High | US$6.35 |
| 52 Week Low | US$2.18 |
| Beta | 0.19 |
| 1 Month Change | -23.48% |
| 3 Month Change | -30.30% |
| 1 Year Change | 19.73% |
| 3 Year Change | -87.25% |
| 5 Year Change | n/a |
| Change since IPO | -91.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 400 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.9% | 3.8% | 1.9% |
| 1Y | 19.7% | -25.3% | 4.6% |
Return vs Industry: 4E2 exceeded the German Pharmaceuticals industry which returned -25.3% over the past year.
Return vs Market: 4E2 exceeded the German Market which returned 4.6% over the past year.
Price Volatility
| 400 volatility | |
|---|---|
| 400 Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4E2's share price has been volatile over the past 3 months.
Volatility Over Time: 4E2's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | Sergio Traversa | www.relmada.com |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc. Fundamentals Summary
| 400 fundamental statistics | |
|---|---|
| Market cap | €107.18m |
| Earnings (TTM) | -€87.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 400 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$94.30m |
| Earnings | -US$94.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 400 perform over the long term?
See historical performance and comparison